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Iron is an essential element in the metabolism of all cells. Elevated levels of the metal have been found in the brains of patients of
numerous neurodegenerative disorders, including Parkinson’s disease (PD). The pathogenesis of PD is largely unknown, although
it is thought through studies with experimental models that oxidative stress and dysfunction of brain iron homeostasis, usually a
tightly regulated process, play significant roles in the death of dopaminergic neurons. Accumulation of iron is present at aﬀected
neurons and associated microglia in the substantia nigra of PD patients. This additional free-iron has the capacity to generate
reactive oxygen species, promote the aggregation of α-synuclein protein, and exacerbate or even cause neurodegeneration. There
are various treatments aimed at reversing this pathologic increase in iron content, comprising both synthetic and natural iron
chelators. These include established drugs, which have been used to treat other disorders related to iron accumulation. This paper
will discuss how iron dysregulation occurs and the link between increased iron and oxidative stress in PD, including themechanism
by which these processes lead to cell death, before assessing the current pharmacotherapies aimed at restoring normal iron redox
and new chelation strategies undergoing research.
1. Introduction
Parkinson’s disease is a chronic, progressive disorder and the
second most common neurodegenerative disease after Alz-
heimer’s disease, with an overall prevalence in the general
population of 0.3% [1]. The incidence of PD increases
with age, making this the most important risk factor. The
cardinal symptoms of tremor, rigidity and postural insta-
bility result from the loss of dopaminergic neurons in the
substantia nigra pars compacta (SNpc) and its projections
in the nigrostriatal tract [2]. Symptoms do not occur until
dopamine levels have been reduced by 70-80%, meaning
that neuroprotection is a crucial but diﬃcult task. In most
PD patients the disease is idiopathic: a combination of
environmental factors and genetic susceptibility. Only 5% of
cases are purely genetic, with a number of genes identified,
serving a vital role in early onset forms of the disease.
The majority of cases are multifactorial—a combination of
factors including accumulation of toxic protein aggregates,
oxidative stress and inflammation.
A further pathological feature of PD is the abnormal ac-
cumulation of iron at aﬀected neurons. Iron plays a vital role
in various physiological functions including DNA synthesis,
mitochondrial respiration, and oxygen transport. Neuronal-
ly, iron is involved inmyelination and neurotransmission and
is the most abundant metal in the brain. Crucially in relation
to PD, the metal acts as a cofactor for tyrosine hydroxylase
(TH), the enzyme at the rate-limiting step in the synthesis
of dopamine. The importance of iron in this process is
underlined by in vitro studies showing that TH activity
is stimulated dose dependently by iron [3]. While iron is
important physiologically in these actions, in excess the
metal can be toxic through oxidative stress. The locations
of iron accumulation in neurological disorders mirror the
regions aﬀected by the relevant condition. This situation is
maintained in PD as increased levels of iron have been found
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in the substantia nigra of PD patients [4–6] and subsequently
implicated in numerous neurological disorders with parkin-
sonism symptoms [7]. It is not clear whether this is a cause
of or a development secondary to neuronal degradation [8].
However, infusion of ferric iron into the SNpc can be used
to create a model of dose-related, progressive parkinsonism
including a reduction in dopaminergic activity [9]. This
can be attenuated by treatment with the lazaroid U-74389G
[10], showing that iron may play a prominent causative
role in the death of neurons by oxidative stress and lipid
peroxidation. It has also been found that chronic exposure
(more than 20 years) to iron and other metals leads to an
increased risk of developing the disease [11], again demon-
strating that excess iron may, at least in part, induce PD
pathogenesis.
Increased iron content is caused by a number of factors
(reviewed in [7]), including a disturbed or “leaky” blood-
brain barrier (BBB), occupational exposure [11] and disrup-
tion of the body’s iron storage and transport mechanisms.
Iron distribution and storage is normally tightly regulated in
the body due to the deleterious eﬀects that iron deficiency
and, as relevant in this discussion, overload have. This com-
plex homeostasis is maintained by the diﬀerential expression
of proteins that regulate its cellular uptake, utilisation, and
storage.
The access of iron to cells is controlled primarily by
transferrin receptors; its storage by the protein ferritin
and pigment melanin (reviewed in [12]), a by-product of
dopamine oxidation. Iron binds to transferrin after carefully
controlled absorption from the duodenum and circulates in
the blood. It is taken into cells via transferrin receptors and
stored in the centre of metalloproteins. Excess iron is stored
as ferritin and lost when cells are shed in the gut. Stored
iron is mobilised from hepatocytes and tissue macrophages
in response to an acute need, with increased intestinal
absorption requested when demand (primarily by erythroid
cells for heme synthesis) exceeds the supply of stored iron
[13]. The levels of ferritin are crucial: iron is relatively
nontoxic when bound to ferritin but alterations in unbound
(free) iron can cause problems, therefore ferritin levels
must be closely regulated. At the posttranscriptional level,
appropriate cellular iron storage is maintained by the iron
regulatory proteins 1 and 2 (IRP1 and IRP2, resp.). When
iron levels are low, IRPs bind to iron responsive elements
(IREs) on the 3′- and 5′-untranslated regions of their
respective mRNAs, thus inhibiting translation of ferritin
RNA and thereby decreasing the iron-storage capacity and
stimulating translation of the transferrin receptor mRNA, a
glycoprotein which controls levels of free-iron. The system
then works in the opposite direction once suﬃcient iron
has been taken up to downregulate the process [14, 15],
helping maintain a storage capacity relative to the level of
iron and the body’s current demands. The importance of
ferritin has been demonstrated through overexpression of
H (heavy chain) ferritin in dopaminergic neurons [16]. The
second important storage protein is intimately related to
nigral neurons. These neurons produce the dark pigment
neuromelanin, which can bind heavy metals, particularly
iron. Loss of melanised neurons is correlated with an
abundance of nonheme iron (Fe3+) and a significant increase
in redox activity, which is most pronounced in patients with
the greatest loss of neuromelanised cells [17].
This change in redox state can contribute to oxidative
stress and induce further cell death. This paper will sum-
marise briefly the factors contributing to a dysregulation
of iron in parkinsonian patients and its role in the disease
pathology before discussing the methods aimed at restoring
iron homeostasis.
2. Molecular Basis of Iron Dysregulation in PD
The full role of iron in the pathogenesis of PD has been
frequently reviewed [18–20] with various interpretations
placed on its significance. Iron toxicity occurs when the levels
of iron exceed the binding capacity of transferrin leading to
an excess of reactive, unbound iron in the body. It is then
sequestered in cells where creating an overload can induce
deleterious eﬀects.
Iron exists in two forms in living organisms: its reduced
form, Fe2+, and the oxidised Fe3+ state. The transfer between
these states, from ferrous iron (Fe2+) to the ferric form
(Fe3+) in a catalytic reaction with hydrogen peroxide (or
molecular oxygen) known as the Fenton reaction, can yield
the highly toxic hydroxyl radical ( •OH) via the Haber Weiss
reaction [21]. The Fenton reaction is a normal metabolic
process, occurring at times including electron transfer in
mitochondria and readily in the cytoplasm where a large
proportion of iron is reduced. However, in PD patients the
ratio of Fe2+ : Fe3+ is 1 : 3 rather than 1 : 1, as in control
brains [22], although this figure can vary between sources
[5]. The iron redox is, therefore, in favour of Fe3+. The
presence of additional iron together with a diminished
supply of antioxidants leads to an increased generation of
hydroxyl radicals through various reactions in the microglia,
producing a cascade of destructive events including oxidative
stress, lipid peroxidation, and eventually apoptosis [23]. The
iron increase in the pathology of PD is not dependent on
systemic iron imbalance, with local dysregulation of the
redox contributing to the overload in the respective tissues
[13].
Under physiological conditions, the free radical species
produced in this reaction are sequestered and inactivated
by the body’s army of antioxidants, including glutathione
(GSH), superoxide dismutase, and catalase. However, a
tip in the balance of the Fenton reaction due to excess
ferrous iron means there is an overwhelming amount of
free radicals produced, which disrupts the normal cellular
redox state. The endogenous cellular defences (which are
relatively low for the amount of oxygen the brain consumes)
are compromised, and oxidative stress follows, triggering a
cascade of deleterious eﬀects throughout the cell. Depleted
glutathione levels have been forwarded as an early factor in
PD pathogenesis [24], as asymptomatic cases of the disease
show a similar pattern of depletion as later in the disease
[25]. But certainly, an increase in antioxidant production
in combination with a compromised cellular defence system
will lead to an increased vulnerability of these cells.
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Maintaining iron redox through processes such as iron
transport sequestration and release is tightly regulated [26].
Any deviation from the normal redox state can have serious
consequences for cells and the organism as a whole due to
the potential iron possesses to become toxic. Ferritin, capable
of sequestering up to 4500 Fe3+ atoms [27] (although it is
rarely saturated [28]), represents an important endogenous
capacity to limit the presence of redox-active iron. The
protein is primarily cytosolic and exists in two subunits
with diﬀerent tasks. The ferroxidase activity of the H-ferritin
subunit converts harmful labile Fe2+ to relatively nontoxic
Fe3+, thereby keeping it in this unreactive form [15, 29].
The L- (light chain) ferritin subunit stabilises this complex
and promotes iron’s long-term storage [27, 30, 31]. The
direct impact of these components in the iron regulatory
system can be evaluated when studying inherited disorders.
Mutations in the gene coding for L-ferritin have been
reported to cause a basal ganglia disorder similar to PD,
highlighting the neurological consequences that excess iron
can have [32].
Imbalance in regulation mechanisms [12] leads to an
increased reactive free-iron pool. Immunohistochemistry
studies show a 60% reduction in iron-transferrin receptor
binding in PD [33], as well as a decrease in transferrin
binding sites [34]. It has been found that in PD brains,
excessive iron is not mirrored by an increase in ferritin
levels [35, 36]—normally brain H-ferritin levels parallel the
increased iron accumulation which occurs with age [37].
Furthermore, in dopamine neurons iron stored within the
ferritin core can be reduced readily by products of dopamine
oxidation such as superoxide and 6-OHDA, adding a further
level of vulnerability to this neuronal population. In an aged
individual, the ferritin can become heavily burdened with the
excess iron, which accumulates with age. Within lysosomes,
ferritin may become degraded releasing the bound iron
and further increasing the level of reactive iron [38, 39].
Therefore, in PD the iron is unbound and free to initiate
a range of cytotoxic and inflammatory eﬀects, such as the
activation of redox-sensitive transcriptional factor nuclear
factor kappa-B (NFκB) and cytokine release from activated
microglia [40].
Oxidative stress is instrumental in PD pathogenesis,
as confirmed by significant neurochemical, histological,
biochemical, and physical evidence and as shown in several
models, including 1-methyl-4-phenyl-1,2,3,6-tetrahydropy-
ridine (MPTP) [41] and rotenone [42], which exert their
neurotoxic eﬀects by free-radical-mediated mitochondrial
dysfunction and oxidative stress [43, 44]. MPTP has also
been implicated in exacerbating iron-related biochemical
abnormalities [45] through an increased expression of the
divalent metal transporter 1 (DMT1) [46]. Oxidative stress
is at a high basal level in the SNpc as the autoxidation
of dopamine produces semiquinones, a toxic species them-
selves, which can also lead to the generation of reactive oxy-
gen species [47] making dopaminergic neurons particularly
vulnerable to iron excess and these subsequent eﬀects. This
level is augmented in PD, partly due to the presence of
additional iron. An excess of iron may lead to a vast increase
in the production of free radicals, which overwhelms the
natural defensive mechanisms and causes damage at several
cellular levels.
Oxidative stress may also impair the ubiquitin-pro-
teasome system, thereby inhibiting cells’ ability to clear
degraded proteins. Iron released from neuromelanin increas-
es oxidative stress in mitochondria, disrupting mitochondri-
al function and reducing the ATP-dependent proteasomal
activity of 26S (the proteasome involved in the ubiquitin
system)—eﬀects which could be reversed in one study by
superoxide dismutase and the iron chelator deferoxamine
[48]. Failure of the proteasomal system to clear these
proteins, which include excess α-synuclein, could lead to
the formation of the proteinaceous inclusions Lewy bodies,
the pathological hallmark of PD [2, 49], and dopamine-
dependent neurotoxicity [50]. Themetal has been implicated
in the formation of these protein aggregates [51]. Along
with other free radical generators (dopamine and hydrogen
peroxide), iron promotes the aggregation of intracellular
aggregates containing α-synuclein and ubiquitin in a human
neuroblastoma cell line overexpressing A53T and A30P
proteins [52].
The process of lipid peroxidation, another event upregu-
lated in PD patients [53], may be induced and can propagate
several eﬀects that threaten cell viability. It can result in the
production of 4-hydroxy-2-nonenol (HNE) [54], a highly
reactive lipophilic α,β-alkenal capable of inducing apoptosis
through a cascade of caspase activation [55], in addition to
promoting DNA fragmentation and contributing to oxida-
tive stress [56]. It has been found that lipid peroxidation
can cause protein aggregation [18], producing Lewy bodies.
Iron may constitute a link between the pathogenic events
of oxidative damage and protein aggregation, with iron
accumulating in Lewy bodies in PD [57] and promoting
alpha-synuclein aggregation [58], an event reversed by the
administration of an iron chelator [59].
It is, therefore, the proficiency of unbound iron to
generate free radicals and induce oxidative stress, which is
at the centre of their deleterious eﬀects. This relationship is
summarised in Figure 1. An imbalance in the normal redox
state of iron, due to an age-related accumulation of iron
in combination with dysregulation of the metal’s storage,
transport, and excretion systems, lead to increased levels of
ferrous iron, which produce free radicals that overwhelm
endogenous cell defences and generate a cascade of cytotoxic
eﬀects. The intimacy of iron storage sites in neuromelanin
to dopaminergic neurons in the substantia nigra mean these
cells are particularly at risk of iron overload-induced death.
3. Iron Chelators as a Treatment
The correlation between iron accumulation in the brain
and PD has logically led to the theory that chelators of
iron could help slow the development of the disease by
mopping up the unbound, free radical-enhancing iron in
the brain. This mode of treatment has precedent: copper
chelation using D-penicillamine has been eﬀective in the
removal of neuronal copper in Wilson’s disease [60]. The
treatment of iron dysregulation in PD at least holds the
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Figure 1: Iron-mediated cell death in PD. Reduced storage capacity in PD due to decreased ferritin expression and degeneration of nigral
melatonin-containing neurons causes an increase in the reactive Fe2+ iron pool. Age-related increases in iron and a leaky BBB cause further
iron accumulation. The transfer of the free iron to ferric iron, Fe3+, in the hydrogen peroxide-mediated Fenton reaction produces the highly
toxic hydroxyl radical. A compromised level of glutathione exacerbates the levels of free radicals, whilst the deamination and autoxidation of
dopamine produces further H2O2. The subsequent oxidative stress can then elicit a range of cytotoxic reactions including protein misfolding,
lipid peroxidation (which, in turn, can cause α-synuclein aggregation), mitochondrial dysfunction, and activation of glial cells. These various
insults can induce cell death by apoptosis, causing further degeneration.
advantage over Alzheimer’s disease (AD) that only one metal
need be targeted, whereas with AD copper and zinc have
also been associated with the disease pathology. Moreover,
chelation of copper using D-penicillamine is ineﬀective
against MPTP-induced dopamine depletion in mice [61].
Clear guidelines exist on the design and structure of a
suitable iron chelator [62]. Potential chelators must have the
ability to selectively scavenge excess intracellular iron and
turn into a nontoxic product, which can be safely excreted.
Since chelation therapy would be maintained for life, it is
important that the agent does not impinge upon levels of
other metals taken in by the diet. Chelators should only
access the intracellular reactive labile iron pool, that is,
iron that is not bound in a ferritin-iron complex as this is
essential for normal physiological functions. The need for
chelators to readily cross the BBB means that the size of
potential chelators is important—300Da being the stated
maximum [63]. There are further substances that have found
neuroprotective benefits in conditions of iron accumulation,
but this is often due primarily to their antioxidant properties
and/or by increasing mitochondrial activity. This paper will
discuss those with proven iron chelating abilities, which
often work in combination with some other neuroprotective
abilities. Table 1 summarises the information outlined in the
following sections, with the modes of action of the chelators
shown in Figure 2.
3.1. Chemical Chelators. Chemical iron chelators are already
available clinically for various conditions. The use of them in
neurodegenerative disorders has been restricted primarily by
their ability (or lack thereof) to cross the BBB in therapeu-
tically eﬃcacious concentrations. But steps have been taken
to overcome these limitations, which has produced a range
of eﬀective drugs to address iron overload in PD by various
means.
3.2. Desferal. Desferrioxamine (also known as deferoxamine,
DFO, or desferal) is a cell-impermeable, highly selective
chelator, which can be taken up by the cell through
endocytosis. It is a hexadentate iron chelator (i.e., it binds
all six of iron’s electrochemical coordination sites) and has
been the most widely used iron chelator over the last 30 years
[78], having been developed for the treatment of secondary
iron overload (such as in β-thalassemia [79]), with the target
primarily being the excess iron present in the liver and spleen.
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Table 1: Iron chelators in brief. Summary of key information regarding iron chelators currently undergoing research as possible PD
therapies.
Chelator name BBB-permeable Stage of research Relevant findings References
Synthetic
Desferal No
Clinically used for systemic
iron accumulation. Cellular
and animal models of PD
Neuroprotective in rat
6-OHDA model
[64]
Deferiprone Yes Phase II trials
Eﬃcacious. Can reduce
iron levels but not always
with symptomatic
improvement
[65, 66]
Apomorphine Yes Animal models
Eﬀective against
iron-induced toxicity and
MPTP-induced cell death
[67]
VK-28 Yes Animal models
Protective in 6-OHDA rat
model
[68]
M30 Yes Animals models
MAO-A and -B inhibitor.
Selective.
Eﬀective in MPTP mouse
model
[69]
M10 Yes Cell culture
Hydroxide scavenger.
Inhibits lipid peroxidation
[70, 71]
CQ Yes Animal models
Neuroprotective in MPTP
mouse model
[72, 73]
Natural
EGCG Yes Animal models
Multiple protective actions.
Can be used in
combination with
rasagiline.
Eﬀective in MPTP mouse
model but not in 6-OHDA
rat model
[74, 75]
Phytic acid Unknown Cell culture
Protects against MPP+ and
6-OHDA toxicity in normal
and excess iron
[76, 77]
Desferal has also been used successfully to chelate iron in
cases of aceruloplasminaemia, as assessed by MRI imaging,
which parallels with improved neurological function [80].
However, this chelator has been unsuccessful previously at
removing small increases in iron, such as in the joints of
rheumatoid arthritis patients, due to adverse eﬀects, which
have been attributed to the high doses used [81]. Some
factors make it unclear whether desferal would be suitable
to treat excessive iron related to neurodegenerative diseases
namely, whether it is able to remove excess iron without
interfering with normal iron metabolism and if these small,
hydrophobic molecules can cross the BBB.
Desferal is reported to attenuate iron-induced oxida-
tive stress and mitochondrial dysfunction and prevent α-
synuclein aggregation in the human neuroblastoma cell line
SK-N-SH in culture [82]. Desferal was eﬀective against
MPP+-induced toxicity in a microdialysis study [83]. The
drug also provided neuroprotection in vivo in a concen-
tration-dependent manner in the 6-OHDA model of PD
[22, 84]. The drug has been eﬀective against dopaminergic
neuron loss in rats [85] and in MPTP-treated mice [86] with
iron overload. Desferal has been shown to attenuate nigral
cell death induced by lactacystin [87]. However, the high
hydrophobic nature and subsequent poor BBB permeability
of desferal means that in these in vivo studies it was delivered
by intracerebroventricular (ICV) injection—clearly not a
viable option for clinical use. Therefore, eﬀective chelators
that can be delivered peripherally and eﬀect iron levels in the
brain are required. More recently, systemic administration of
desferal at 30mg/kg has been shown to be neuroprotective
in the 6-hydroxydopamine (6-OHDA) model of PD and
reduced hydroxyl radical formation [64]. There has been
much progress delineating the mechanism and safe doses of
desferal. However, the diﬃculty of administering the drug
clinically limits its use sharply.
3.3. Deferiprone. The chelator deferiprone, used in the treat-
ment of thalassaemia major, has the great advantage of being
orally active; meaning the complex and mostly impractical
administration routes of desferal may be avoided. It has
been reported to be successful after 6 months of therapy in
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Figure 2: Action of iron chelators targeting PD. All iron chelators mop up excess free, reactive iron, thus reducing the reduction of Fe2+ to
Fe3+—a reaction that produces various ROS, such as the hydroxyl radical. Oxidative stress resulting from the generation of ROS produces a
range of deleterious insults, which can be targeted with the multiple actions of inhibitors. This can attenuate the cell death that these events
induce. Chelators with antioxidant properties inhibit the production of ROS, in an environment of diminished antioxidant activity. The
dopamine-oxidising enzyme MAO-B, which resides in the outer membrane of mitochondria, can also be inhibited by some chelators.
one case of neurodegeneration associated with brain iron
overload, with an improvement of gait and reduction in
dyskinesias [65], demonstrating that the drug can cross the
BBB in eﬃcacious concentrations. This led to the develop-
ment of a Phase II trial for deferiprone to assess its safety
and eﬃcacy as a chelator of excess iron in the treatment for
PD, with low doses being favoured (15mg/kg/day). Patients
are to be assessed every 3 months by unified PD rating
scale (UPDRS) and, when possible, by magnetic resonance
imaging [88]. Further clinical trials are assessing deferiprone
at diﬀerent doses in aged individuals [89, 90]. A smaller
Phase II pilot study has already been completed, assessing the
safety and eﬃcacy of deferiprone on targeting globus pallidus
iron in patients aﬀected by pantothenate kinase-associated
neurodegeneration (PKAN), a genetic disorder where levels
of cysteine, an eﬃcient iron binder, increase in the basal
ganglia. The study, which nine patients completed, shows
that 6 months of treatment leads to a significant reduction
in iron content in this brain region, as measured by MRI,
although the clinical status of patients did not change [66].
However, the patients in the study were not aged (the range
being 7–39 years old), so whether deferiprone would be
equally well tolerated in older PD patients is not certain. But
the clear eﬃcacy in reducing iron content in this form of
neurodegeneration with brain iron accumulation (NBIA) is
promising andmay be well transferred to PD patients. Earlier
intervention could be required to provide a symptomatic
benefit.
3.4. Apomorphine. Pretreatment with R-apomorphine, a D1-
and D2-receptor agonist, which can be used as a Levodopa
replacement therapy in late-stage PD, shows antioxidant
and iron-chelating abilities in the MPTP model due to
its catechol structure [91]. The authors report that the
dopamine agonist property is not behind the neuroprotective
ability of the drug in this model, with a combination of
iron chelating and, primarily, radical scavenging capacities
accounting for the protection aﬀorded [92]. This is because
the nondopaminergic receptor agonist isomer of the drug,
S-apomorphine, retains the same neuroprotective properties
[93]. A broad spectrum of neuroprotective abilities is shown
again by R-apomorphine in vitro [94]. These studies confirm
that both inhibit the reduction in GSH, again confirming
the benefit of a drug with multiple neuroprotective actions.
The comprehensive assessment of R-apomorphine by [67]
demonstrates the drug’s neuroprotective actions against 6-
OHDA- and iron-induced toxicity in vitro as well as inMPTP
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mouse models. These include inhibition of iron-mediated
lipid peroxidation, meaning this agent elicits an extensive
range of actions to counter the damage caused by iron
accumulation.
3.5. Hydroxyquinolines. Hydroxyquinoline is a bidentate
chelator containing the 8-hydroxyquinoline (8-HQ) moiety.
This structure forms stable 5-membered chelate rings with
Fe3+ [95]. 8-HQ, a highly lipophilic complex, readily pene-
trates cell membranes and the BBB and, therefore, has been
used as the base for orally eﬀective chelators, including VK-
28, M30, and clioquinol, all of which will be discussed.
VK-28 is an iron chelator with a potency comparable
to desferal. However, in contrast to desferal, VK-28 is BBB-
permeable. It is neuroprotective against 6-OHDA toxicity in
rats when given either by ICV or intraperitoneal routes with-
out altering peripheral ironmetabolism. In the absence of the
toxin, VK-28 has no eﬀect on the basal levels of transmitters
such as dopamine, showing that the iron-dependent rate-
limiting enzymes TH and tryptophan hydroxylase are not
aﬀected [68].
Since VK-28 so far meets all the needs of an iron
chelator, derivatives of VK-28 have been generated. M30,
a potent brain-selective inhibitor of monoamine oxidase-
A and -B (MAO-A and MAO-B, resp.) based around the
pharmacore of VK-28, is eﬀective in both cell culture [70]
and the MPTP mouse model [69]. It also restores levels
of the antiapoptotic protein Bcl-2 in mice treated with
microinjections of lactacystin [71]. Both M30 and parent
molecule VK28 showed behavioural improvements in this
model [70]. M30 also prevents iron-dependent hydroxyl
radical generation [96]. Part of this bifunctional protection
is explained by the drug sharing some structural units with
rasagiline, a selective irreversible MAO-B inhibitor [97].
M10 is another hydroxyquinoline derivative with radical
scavenging and iron-chelating properties. It is a potent
hydroxide scavenger and has been shown to be as eﬀective as
rasagiline in PC10 cell culture and inhibits lipid peroxidation
with an IC50 value comparable to desferal [96].
Antibiotics have been shown to have iron-chelator prop-
erties. 5-chloro-7-iodo-hydroxyquinoline (or clioquinol/
CQ) was at the centre of one of the worst drug disasters
of the 20th century, when thousands of people worldwide
developed subacute myelo-optic neuropathy (SMON) after
using the drug to treat intestinal infections. This pathology
was later linked to the drug’s promotion of vitamin B12
excretion [72]. It has long been known that clioquinol
chelates iron [98]. More recently it has been studied for its
iron-chelating properties in neurodegenerative diseases. CQ
has been reported to be eﬀective against β-amyloid aggrega-
tion in AD transgenic mice [99] in a study targeting copper
and zinc interactions, showing that CQ is not a selective
iron chelator. However, despite this apparent drawback when
considering the guidelines outlined [78], the converse was
the case, as copper can also facilitate Fe2+ toxicity [99].
Toxic side eﬀects have been a problem when using other
iron chelators; the low lipid solubility of which hinders their
ability to cross the BBB meaning higher doses are required.
The lipophilic nature of CQ allows for its eﬀective use at
lower concentrations [72, 73]. CQ provided neuroprotection
in MPTP-treated mice [73] after 8 weeks of oral treatment
in addition to a reduction in motor dysfunction. CQ led
to decreased bioavailable iron levels in normal mice [72],
with the drug well tolerated in both studies, an important
consideration to make since any clinical treatment is likely to
be for life.
3.6. Natural Chelators. This group includes components of
plant polyphenols, such as epigallocatechin gallate (EGCG),
a green tea extract (catechin). These compounds have been
utilised over many years for their antioxidant properties
and have been investigated for their potential use in several
diverse areas including oncology, cardiology, and neurology.
The favourable properties of green tea (GT) are attributed to
their high content of antioxidant polyphenic flavanoids, of
which there is a vast array—over 4000 flavanoids have been
identified [100]. GT catechins possess structures which infer
metal chelating properties—the 3′,4′-dihydroxyl group and
the gallate groups are present. These may neutralise ferric
iron to produce a redox-inactive form [101]. The compounds
are nontoxic and readily cross the BBB, meaning the ease of
administration is a major advantage, with epidemiological
evidence showing that drinking two cups of green tea a day
reduces the risk of PD [102].
3.7. EGCG. The most abundant and pharmacologically
active green tea extract, EGCG, has been shown to be
attenuate striatal dopamine and TH loss as well as nigral
dopaminergic cell death in MPTP-treated mice [103]. The
authors propose various mechanisms for this protection
including acting as an antioxidant, preventing lipid perox-
idation and inhibiting MAO-B in addition to its role as
an iron chelator. An agent which could work by various
pathways would be highly beneficial due to the multifactorial
nature of PD. Catechins have also been shown to regulate
various signalling pathways involved in cellular survival and
downregulate proapoptotic pathways (reviewed in [104]),
as well as inhibit catechol-O-methyltransferase (COMT)
activity [105]. Together with its iron-chelating activities, this
data mean green tea extracts are powerful agents to use when
cell death may be mediated by oxidative stress.
EGCG has been tested in combination with the estab-
lished anti-PD drug rasagiline [74]. EGCG is relatively a
far weaker MAO-B inhibitor than rasagiline (with an IC50
of 662 μM compared to 6 nM [103]); therefore, if this
pharmacological requirement could be supplemented by
another drug, the neuroprotective eﬀect may be augmented.
It was found that the two act synergistically to provide neu-
roprotection in the MPTP mouse model [74].
However, EGCG has proven less successful in the 6-
OHDA rat model as only subtle behavioural improvements
in the absence of neuroprotective benefits were produced
when given orally [75]. This may be due to the doses admin-
istered (1-2mg/kg: physiological dose), which, although
eﬀective against MPTP-induced neuronal degradation [103],
were too low for this particular model due to the mechanism
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of toxicity. Therefore, it is important to consider the actions
of individual PD models when evaluating the eﬀectiveness of
these compounds.
3.8. Phytic Acid. Phytic acid (IP6, myoinositol hexakisphos-
phate) is an antinutrient and has previously been shown to
be eﬀective in cancer through an antioxidant eﬀect [106].
The agent has been studied for its beneficial antioxidant
properties on hydroxyl radical formation enhanced by Fe2+
induced by MPP+ in rat striata. Here phytic acid chelated
iron required for radical formation via the Fenton reaction
[107]. It has since been demonstrated to be protective
against MPP+-induced toxicity in immortalised rat mesen-
cephalic/dopaminergic cells by attenuating caspase-3 activity
and DNA fragmentation, and increasing cell viability in both
conditions of normal and excess intracellular iron content
[76]. This eﬀect was replicated in a cell culture model
utilising 6-OHDA [77]. Phytic acid has been forwarded as a
safer alternative to synthetic iron chelators, such as desferal,
although there remains some concern about the compound’s
ability to cross the BBB. Studies in PDmodels are also limited
at this stage. Further work is required with this compound to
fully assess its potential clinical benefit.
These groups of natural chelators meet all the require-
ments for an iron chelator to be eﬀective in providing neuro-
protection in PD. The range and vast number of compounds
available mean there are many more similar structures which
can be screened. Further tests in models of PD would allow
them to be eﬀectively evaluated.
4. Conclusions
There is strong evidence that iron accumulation causes cell
death, particularly in the substantia nigra through oxidative
stress mechanisms. Deposits of the metal are found in the
substantia nigra of PD patients, whilst local administration
of the metal can cause degeneration and reductions in
dopamine levels. Iron is involved in various biochemical
reactions, with the Fenton reaction at the centre of this
redox balance. The transfer between the two ion states is
a tightly regulated process, in which storage and transfer
proteins work concurrently to maintain physiological levels
of iron. An influx of the metal causes an increase in the
levels of reactive ferric iron and results in more harmful
reactive species. Deleterious consequences including lipid
peroxidation, reduction in levels of endogenous antioxidants
and stimulation of cellular apoptotic cascades escalate cell
death in these areas. Iron chelators have the potential to
address the balance in the available level of the reactive iron
form (labile iron pool) to prevent the overproduction of
oxidative species.
Established iron chelators, which have been used in con-
ditions of iron excess for many years, such as desferrioxam-
ine/desferal, have now found a new use in neurodegenerative
diseases. But desferal’s inability to cross the BBB means
this drug will never be a feasible option in its initial form.
However, the drug’s use as a base for orally active agents,
which retain these iron chelating activities, is more signifi-
cant. Of the putative treatments, deferiprone is certainly at
the most advanced levels of research. Having found success
in experimental models, the recent commissioning of Phase
II clinical trials investigating the agent will provide further
information regarding the safety and tolerability in aged
patients.
A major advantage of these new pharmacotherapies
is the mixture of neuroprotective actions they possess. In
addition to iron chelation, recent therapies also have MAO-
B inhibition capabilities and antioxidant properties. This
allows for a more comprehensive mode of action, which is
what is required in PD where a plethora of pathologies exist.
Antioxidant actions of natural substances, such as the green
tea extract EGCG, have been coupled with iron chelation
activities to provide natural alternatives.
However, due to the ubiquitous nature of iron, it is
important to consider whether iron chelators will provide
the cellular specificity required to remove excess iron from
the appropriate tissue, without aﬀecting systemic iron home-
ostasis. The dose of chelator is an important factor to con-
sider in treatment so that the correct tissues are penetrated
and systemic iron levels are not altered.Moreover, subcellular
locations of ironmay need to be recognised. Li and colleagues
[108] discuss the importance of specificity of intracellular
targets for iron chelation in relation to Friedreich’s ataxia
(FA). Iron chelators, therefore, may be required to remove
iron in a highly selective manner whilst stabilising iron levels
elsewhere even within the same cell. Initial clinical trials [65]
demonstrate that doses of deferiprone are well tolerated over
the long term (6 months) with no stated propagation of a
challenge to systemic iron homeostasis. The early successes
of these patient studies demonstrate that this issue may not
be as pertinent in PD as in FA. Furthermore, deferiprone
itself has been shown to be highly selective when used at low
concentrations in FA patients—relocating iron from areas
of accumulation in the brain to ferritin, thereby preventing
deprivation in other tissues [109].
The presence of increased levels of iron in the areas
aﬀected by degeneration in PD together with the eﬀects
this dysregulation have, mean reversing this redox imbalance
is an important aim for any neuroprotective therapy. Iron
chelators initially used for other medical applications have
been built upon with their functions adapted to suit the
pathology of PD. With some treatments now reaching
clinical trials, it is hoped that an eﬃcacious and tolerable
iron chelation therapy, which is eﬀective at attenuating
neurodegeneration, is close to being achieved.
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